Details for New Drug Application (NDA): 019123

NDA 019123 describes KLOR-CON, which is a drug marketed by Upsher Smith Labs and is included in four NDAs. It is available from seven suppliers. Additional details are available on the KLOR-CON profile page.

The generic ingredient in KLOR-CON is potassium chloride. There are two hundred and forty drug master file entries for this compound. Eighty-eight suppliers are listed for this compound. Additional details are available on the potassium chloride profile page.

Summary for 019123

Tradename:	KLOR-CON
Applicant:	Upsher Smith Labs
Ingredient:	potassium chloride
Patents:	0

Pharmacology for NDA: 019123

Mechanism of Action	Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption

Suppliers and Packaging for NDA: 019123

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
KLOR-CON	potassium chloride	TABLET, EXTENDED RELEASE;ORAL	019123	NDA	Upsher-Smith Laboratories, LLC	0245-5315	0245-5315-01	100 BLISTER PACK in 1 BLISTER PACK (0245-5315-01) / 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK (0245-5315-89)
KLOR-CON	potassium chloride	TABLET, EXTENDED RELEASE;ORAL	019123	NDA	Upsher-Smith Laboratories, LLC	0245-5315	0245-5315-11	100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0245-5315-11)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	8MEQ
Approval Date:	Apr 17, 1986	TE:	AB2	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EXTENDED RELEASE;ORAL			Strength	10MEQ
Approval Date:	Apr 17, 1986	TE:	AB2	RLD:	Yes

Complete Access Available with Subscription